Search
Global
中文版 English
Search

# Hot Search #

EVOMELA CNTC19 BI-1206 CID-103
Home Media Press Releases
Press Releases
Press Releases Media Library Media Contact
Filter by year
ALL 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2005
CASI Pharmaceuticals Reports Development Relating To Its Disputes With Juventas
Apr 09, 24
CASI Pharmaceuticals Reports Development Relating To Its Disputes With Juventas

javascript:;
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
Mar 29, 24
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results

javascript:;
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
Mar 05, 24
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China

javascript:;
CASI Pharmaceuticals Announces First Dosing of FOLOTYN ® in China
Feb 19, 24
CASI Pharmaceuticals Announces First Dosing of FOLOTYN ® in China

javascript:;
CASI Pharmaceuticals Announces Strategic Partnership with China National Medicines Corporation
Feb 01, 24
CASI Pharmaceuticals Announces Strategic Partnership with China National Medicines Corporation

javascript:;
CASI Pharmaceuticals Announces Third Quarter 2023 Business and Financial Updates
Nov 14, 23
CASI Pharmaceuticals Announces Third Quarter 2023 Business and Financial Updates

javascript:;
CASI Pharmaceuticals Announces Market Approval Of CNCT19 By China NMPA
Nov 09, 23
CASI Pharmaceuticals Announces Market Approval Of CNCT19 By China NMPA

javascript:;
CASI Pharmaceuticals Announces Second Quarter 2023 Business and Financial Updates
Aug 11, 23
CASI Pharmaceuticals Announces Second Quarter 2023 Business and Financial Updates

javascript:;
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals
Aug 01, 23
Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

javascript:;
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics’ VCP/P97 Inhibitor CB-5339
Jul 21, 23
CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics’ VCP/P97 Inhibitor CB-5339

javascript:;
CASI Pharmaceuticals Announces First Quarter 2023 Financial Results
May 17, 23
CASI Pharmaceuticals Announces First Quarter 2023 Financial Results

BEIJING, May 17, 2023 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the three months ended March 31, 2023.
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022
Apr 26, 23
CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

BEIJING, April 26, 2023 - CASI Pharmaceuticals, Inc. (NASDAQ: CASI) (“CASI” or the “Company”), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) on April 26, 2023. The annual report can be accessed on the Company’s investor relations website at https://www.casipharmaceuticals.com/investor-relations/ as well as the SEC’s website at https://www.sec.gov/.

CASI Pharmaceuticals © 2023 CASI Pharmaceuticals Inc.
All Rights Reserved.

Quick links
About Portfolio Media Investors Careers Report a Side Effect
Stay Connected
hr@casi.cn Send mail
Contact Us Privacy Terms of User Cookies Sitemap
Powered by Pousion